Granuflo lawyer | Granuflo lawyer |

Fresenius (FMC) neglected to warn the public about the risks of using GranuFlo. An internal memo issued by Fresenius on November 4, 2011, disclosed that there was a significant risk of cardioplumonary arrest and death for patients undergoing dialysis treatment at their clinics due to the incorrect dialysate concentration. This information was only shared with physicians and clinics associated with FMC. According to their report, 941 patients treated at FMC clinics had cardiac arrests during or shortly after treatment. The thousands of other clinics that were using these products were not notified of the problem until March 2012. The FDA is currently undergoing an investigation to see if Fresenius’ failure to issue an earlier warning violates federal law.